(MENAFN- GlobeNewsWire - Nasdaq) Pune, India, Aug. 09, 2023 (GLOBE NEWSWIRE) -- According to our latest study on " arterial blood gas kits market Size Report, Forecast to 2030 – COVID-19 Impact and Global Analysis – by Product, Type, Usage, Application, Needle Gauge, Syringe Volume, and End User," the market is expected to reach $1.21 billion by 2030 from $0.695 billion in 2022, it is estimated to grow with a CAGR of 7.2% from 2022 to 2030. The arterial blood gas kits market majorly consists of the players, Radiometer Medical ApS; Vyaire Medical Inc; Opti Medical Systems; ITL health Group Ltd; Teleflex Inc; Becton Dickinson and Co; ICU Medical Inc; SunMed LLC; Trudell Healthcare Solutions Inc; Siemens Healthineers AG; Medline Industries LP; Cardinal Health Inc; and Fisher Scientific International.

Download Sample PDF Brochure:

An arterial blood gas (ABG) is a blood test carried out by taking blood from an artery, rather than a vein. It is performed to obtain accurate measurements of oxygen and carbon dioxide levels, which then allows the oxygen to be delivered appropriately. The increasing prevalence of respiratory diseases and metabolic and kidney diseases are driving the arterial blood gas kits market. However, risks, complications, and sampling errors associated with arterial blood sampling hinder the arterial blood gas kits market growth.

Global Arterial Blood Gas Kits Market – Report Scope:

Report Coverage	Details
Market Size Value in	USD 0.695 Billion in 2022
Market Size Value by	USD 1.21 Billion by 2030
Growth rate	CAGR of 7.2% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022
No. of Pages	226
No. of Tables	193
No. of Charts & Figures	73
Historical data available	Yes
Segments covered	Product, Type, Usage, Application, Needle Gauge, Syringe Volume, and End User

Global Arterial Blood Gas Kits Market: Competitive Landscape and Key Developments
Radiometer Medical ApS; Vyaire Medical Inc; Opti Medical Systems; ITL Health Group Ltd; Teleflex Inc; Becton Dickinson and Co; ICU Medical Inc; SunMed LLC; Trudell Healthcare Solutions Inc; Siemens Healthineers AG; Medline Industries LP; Cardinal Health Inc; and Fisher Scientific International, Inc are a few key companies operating in the arterial blood gas kits market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the arterial blood gas kits market. A few of the recent developments in the global arterial blood gas kits market are mentioned below:

In April 2020, Siemens Healthineers received the US Food and Drug Administration (FDA) approval for RAPIDPoint 500e blood gas analyzer. RAPIDLyte Arterial Sampling Syringes and RAPIDLyte Multicap Capillaries offered by Siemens are compatible with RAPIDPoint 500e blood gas system. This product approval strengthens the market position of the company.

In February 2020, Becton, Dickinson and Company (BD) and Babson Diagnostics entered into a long-term strategic partnership agreement. The partnership helps to develop and deliver standard laboratory-quality, small-volume arterial blood gas collection kits such as BD Vacutainer at retail pharmacies. The partnership allows the company to build its distribution network to increase product penetration in the respective markets.

Browse key market insights spread across 226 pages with 193 list of tables & 73 list of figures from the report , "Arterial Blood Gas Kits Market Forecast to 2030 - COVID-19 Impact and Global Analysis by Product (Luer Lock Syringe and Luer Slip Syringe), Type (Non-Vented and Vented), Usage (Pre-set Plunger Mode and Manual Aspiration), Application (In Vitro Diagnostics, Electrolyte Analysis, and pH Blood Gas), Needle Gauge (23G to 25G and Less than 23G), Syringe Volume (1 ml, 3 ml, and Others), and End User (Hospitals, Clinics, and Others)" in detail along with the table of contents:

Growing Prevalence of Metabolic and Kidney Diseases Drives Global Arterial Blood Gas Kits Market Growth:
Arterial blood gas test kits are used to detect an acid-base imbalance that can cause kidney failure; heart failure; and metabolic diseases, such as diabetes. Thus, the test is prescribed to people suffering from metabolic and kidney diseases. As per the report titled“Global and regional diabetes prevalence estimate for 2019 and projections for 2030 and 2045,” the prevalence of diabetes is estimated to be 9.3% (463 million) across the world in 2019, rising to 10.2% (578 million) and 10.9% (700 million) by 2030 and 2045, respectively. Furthermore, as per the National Kidney Foundation, an estimated 37 million people (i.e., 15% of the adult population) in the US suffer from chronic kidney disease (CKD). It also mentioned that, in 2018, ∼785,883 Americans were suffering from kidney failure and needed dialysis or a kidney transplant to survive. Additionally, as per Kidney Care UK, the UK records ∼ 20 cases of kidney failure daily. It also mentions that the country reports ∼40–45,000 premature deaths every year due to CKD. Thus, the high prevalence of metabolic and kidney diseases drives the growth of the ABG kits market.

Impact of COVID-19 Pandemic on Global Arterial Blood Gas Kits Market:
The global economy was severely affected due to the COVID-19 pandemic. However, atrial blood gas kits were experiencing a steady increase in demand before the COVID-19 pandemic. Countries experienced a rise in COVID-19-positive cases, which created the demand for arterial blood gas test kits for examining purposes. The market has experienced exponential growth during the pandemic due to tremendous demand for oxygen level testing through arterial blood gas kits. Various factors, including increased incidences of COVID-19, growth in arterial blood gas kit technologies, and rise in the production of kits, supported the market growth. In addition, growing research on arterial blood gas analysis of COVID-19 patients positively impacts the market. For instance,“Arterial Blood Gas Analysis of Critically Ill Corona Virus Disease 2019 Patients” was published in the Asian Journal of Research in Infectious Diseases in April 2021. The study concluded that the ABG test performed on critically ill COVID-19 patients offers valuable information on the underlying pathophysiology. The availability of vaccines and other healthcare facilities in developing countries and support from other developed countries is expected to provide an opportunity for the market growth; for instance, in June 2020, WHO delivered 20 arterial-blood gas (ABG) analysis devices to the Islamic Republic of Iran to support the country's fight against COVID-19. This shipment, funded by the Government of Japan, is the second of two medical aid deliveries, including a total of 75 ABG analyzers. Therefore, the COVID-19 pandemic had a substantial positive impact on the arterial blood gas kits market.

Directly Purchase this Report at

Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

arterial blood gas analyzers market Forecast to 2028 - COVID-19 Impact and Global Analysis

blood gas and electrolyte analyzer market Forecast to 2028 - Covid-19 Impact and Global Analysis

veterinary point of care blood gas analyzers market Forecast to 2028 - Covid-19 Impact and Global Analysis

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur
E-mail :
Phone : +1-646-491-9876
Press Release :
Industry Research :

Tags arterial blood gas kits market arterial blood gas kits luer lock syringe luer slip syringe in vitro diagnostics ph blood gas

MENAFN09082023004107003653ID1106817719